RT Journal Article SR Electronic T1 Estimating stem cell fractions in hierarchically organized tumors JF bioRxiv FD Cold Spring Harbor Laboratory SP 013672 DO 10.1101/013672 A1 Benjamin Werner A1 Jacob G. Scott A1 Andrea Sottoriva A1 Alexander R.A. Anderson A1 Arne Traulsen A1 Philipp M. Altrock YR 2015 UL http://biorxiv.org/content/early/2015/01/11/013672.abstract AB Cancers arise as a result of genetic and epigenetic alterations. These accumulate in cells during the processes of tissue development, homeostasis and repair. Many tumor types are hierarchically organized and driven by a sub-population of cells often called cancer stem cells. Cancer stem cells are uniquely capable of recapitulating the tumor and can be highly resistant to radio-and chemotherapy treatment. We investigate tumor growth patterns from a theoretical standpoint and show how significant changes in pre-and post-therapy tumor dynamics are tied to the dynamics of cancer stem cells. We identify two characteristic growth regimes of a tumor population that can be leveraged to estimate cancer stem cell fractions in vivo using simple linear regression. Our method is a mathematically exact result, parameter free and does not require any microscopic knowledge of the tumor properties. A more accurate quantification of the direct link between the sub-population driving tumor growth and treatment response promises new ways to individualize treatment strategies.Significance Statement Under the cancer stem cell hypothesis a tumor population is driven by a fraction of self-renewing cancer stem cells. Absolute and relative size of this population in human cancers at any stage of the disease remains unknown. We formulate a mathematical model that describes the tumor cell population’s growth dynamics and response to therapy. This allows to estimate cancer stem cell fraction from longitudinal measurements of tumor size (often available from imaging). Such estimates are critical because treatment outcome and risk of relapse depend on the tumor’s capacity to self-renew. Ideally, by tailoring patient treatment strategies based on the relative abundance of cancer stem cells could lead to radically different therapeutic regime and to the successful eradication of the disease.